231 related articles for article (PubMed ID: 25199408)
21. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
22. Ponatinib superior to imatinib in Ph
Sidaway P
Nat Rev Clin Oncol; 2024 Jul; 21(7):483. PubMed ID: 38806653
[No Abstract] [Full Text] [Related]
23. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
24. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
[TBL] [Abstract][Full Text] [Related]
25. Ponatinib in Philadelphia chromosome-positive leukemias.
Quintas-Cardama A
N Engl J Med; 2014 Feb; 370(6):577. PubMed ID: 24499222
[No Abstract] [Full Text] [Related]
26. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
[TBL] [Abstract][Full Text] [Related]
27. Should vascular effects of newer treatments be addressed more completely?
Yang EH; Watson KE; Herrmann J
Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
[No Abstract] [Full Text] [Related]
28. Where exactly does ponatinib fit in chronic myelogenous leukemia?
Berman E
J Natl Compr Canc Netw; 2014 Nov; 12(11):1615-20. PubMed ID: 25361807
[TBL] [Abstract][Full Text] [Related]
29. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sanford DS; Kantarjian H; O'Brien S; Jabbour E; Cortes J; Ravandi F
Expert Rev Anticancer Ther; 2015 Apr; 15(4):365-73. PubMed ID: 25764322
[TBL] [Abstract][Full Text] [Related]
30. [3rd generation ABL kinase inhibitor and Philadelphia chromosome positive leukemia].
Tauchi T
Rinsho Ketsueki; 2013 Oct; 54(10):1682-6. PubMed ID: 24064817
[No Abstract] [Full Text] [Related]
31. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
32. Cancer-drug discovery and cardiovascular surveillance.
Groarke JD; Cheng S; Moslehi J
N Engl J Med; 2013 Nov; 369(19):1779-81. PubMed ID: 24180496
[No Abstract] [Full Text] [Related]
33. Ponatinib in Philadelphia chromosome-positive leukemias.
Cortes JE; Talpaz M; Kantarjian H
N Engl J Med; 2014 Feb; 370(6):577. PubMed ID: 24499221
[No Abstract] [Full Text] [Related]
34. Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study.
Millot F; Suttorp M; Versluys AB; Kalwak K; Nelken B; Ducassou S; Bertrand Y; Baruchel A
Eur J Cancer; 2020 Sep; 136():107-112. PubMed ID: 32668374
[TBL] [Abstract][Full Text] [Related]
35. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
[No Abstract] [Full Text] [Related]
36. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
Boo YL; Liam CCK; Toh SG; Lim SM
Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
[No Abstract] [Full Text] [Related]
37. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
38. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.
Müller MC; Cervantes F; Hjorth-Hansen H; Janssen JJWM; Milojkovic D; Rea D; Rosti G
Crit Rev Oncol Hematol; 2017 Dec; 120():52-59. PubMed ID: 29198338
[TBL] [Abstract][Full Text] [Related]
39. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
Chen H; Xu LP; Zhang XH; Wang Y; Chen YH; Yan CH; Cheng YF; Han W; Chen Y; Qin YZ; Liu Y; Chang YJ; Liu KY; Huang XJ
Leuk Res; 2022 Oct; 121():106930. PubMed ID: 36007342
[TBL] [Abstract][Full Text] [Related]
40. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
Nickel RS; Daves M; Keller F
Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]